All In Biotech

Drug Trial Radar · NCT02390089

Cough According to Stimulus Type in PD

Airway Protection Deficits According to Stimulus Type in Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Feb 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

158

Actual

Start

Apr 2015

Primary completion

Feb 10, 2017

Study completion Feb 13, 2019

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted
Mar 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Aspiration pneumonia (APn) occurs at a higher rate in patients with Parkinson's disease (PD) versus healthy adults. This is of particular public health concern given that death secondary to aspiration pneumonia and lung infection is a leading cause of death in persons with PD. Swallowing and cough function are affected in PD, putting people with PD at significant risk for uncompensated aspiration (aspiration without adequate cough response). One challenge in the management of airway protective deficits related to PD is the chronic and progressive nature of the disease, where swallowing dysfunction appears subtly in the form of microaspiration, reducing the perceived urgency of the swallowing disorder by both clinicians and patients. The long-term goal of this research is to advance the management of airway protection deficits in patients with neurodegenerative disease in order to decrease morbidity and mortality due to aspiration related lung infection. The objective here is to further specify deficits leading to uncompensated airway compromise in PD in order to advance the clinical management of these patients, leading to an immediate positive impact.

Conditions

  • Parkinson's Disease

Interventions

  • Capsaicin vaporDrug

    Single-breath and continuous inhalation paradigm to induce cough.

  • fogOther

    Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)

  • Videofluoroscopic swallow evaluationRadiation

    Fluoroscopic evaluation of oropharyngeal swallowing function.

  • NebulizerDevice

    A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urge-to-cough sensitivityTime frame: 30 minute
  2. Positive/negative cough responseTime frame: 10 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida Center for Movement Disorders and Neurorestoration

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.